Our understanding of the menopause and the management of its issues is in a continual state of flux. Since the publication of the original Women's Health Initiative study and the immediate conclusions and position statements from various specialist societies and regulatory authorities, clinicians have had little choice other than to significantly change their clinical management.
So, is this a change for good? Whether you were a supporter or detractor of hormone replacement therapy (HRT), or even sat on the academic fence you will be aware that many clinicians have withdrawn from even discussing the place of HRT in the management of menopausal issues with their patients. This cannot be a good thing. Provision of a truly holistic approach towards the management of the menopause must include at least a discussion of hormone therapy and its good and bad points. Is there really a reluctance of the professional groups involved to talk to women and has this reluctance led to fewer women coming to see their carers? Are more women suffering as a result? No clear data exist except for the precipitous fall in the numbers of prescriptions of hormone therapies over the majority of the last decade.
Apart from the proven clinical benefits of HRT, it should not be forgotten that the whole process of receiving hormone therapy resulted in a woman following a care pathway that was almost entirely about disease and illness prevention. Symptom control, the commonest reason for presentation in the early days of HRT availability, started to become overtaken by women seeking some of the putative preventive properties of HRT.
We currently have a population of women, the majority of whom are likely to be suffering menopausal symptoms, experiencing progressive bone loss and symptoms of lower genital tract atrophy. They may be reluctant to consider HRT because they are worried about the risks of the drug or because they are aware that their carers are reluctant to prescribe it. This is, of course, a missed opportunity to practise preventive health care. These women can be helped in many other ways, not just with HRT and it is therefore important that the message is clearly spread that the caring professions can helpengage us and we will do our best to educate and where necessary treat using whatever is most appropriate with the most up-to-date information at our disposal.
These are exciting yet challenging times for anyone involved in postreproductive health treatment and research. Lessons learnt from the big studies published early in the last decade and subsequent studies that challenge some of the conclusions are appearing. A new optimism in this area of medicine is surfacing and anyone working in postreproductive health care needs to keep a close eye on the data.
In 2010, there has also been a change in the editorship of Menopause International. We thank John Studd for his hard work on the journal over the last year and wish him well. Our aim is to take the journal forward in terms of its abilities to keep its readership stimulated by original work, kept up-to-date with the News section, have CPD requirements met with the introduction later this year of a new style of review articles and many other changes. For these changes to be effective we would like this to be a two-way process with the readership. We welcome letters about what we publish and will, when possible, publish them. We also welcome your original articles that we undertake to rapidly subject to peer review.
While writing this editorial, 2010 has just started and it is a time when many consider New Year resolutions to incentivize personal change. May we suggest that, regardless of whether you have made a resolution or not you resolve to keep as up-to-date as possible in this rapidly changing area or, better still, share your knowledge with your peers through Menopause International. 
